About us

Holostem Terapie Avanzate is a university spin-off, founded in 2008, through the profitable union among the scientific know-how of internationally renowned researchers such as Michele De Luca and Graziella Pellegrini, the innovative spirit of the University of Modena and Reggio Emilia and the industrial know-how of Chiesi Farmaceutici S.p.A., a leading Italian pharmaceutical company.


Read more >

Therapeutic Areas

Ocular Surface
The first product,  Holoclar®, registered in Europe in 2015, is based on autologous cultures of limbal stem cells for the regeneration of destroyed corneal epithelium.



Skin
Holostem Terapie Avanzate  is collaborating with CMR on the implementation of two Phase I/II clinical trials for ex-vivo gene therapy of Epidermolysis Bullosa (EB)



Other Tissues
The future R&D activity of Holostem Terapie Avanzate is aimed at the development of new cell and gene therapy products based on different epithelial stem cells and other somatic stem cells. 


Read more >


News

© 2015  Holostem Terapie Avanzate S.r.l.
Via Glauco Gottardi 100 - 41125 Modena - Italy 
Phone: +39 059 2058064 - Fax: +39 059 2058115 - Email: info@holostem.com

VAT: 03213240363 - Payed Up Capital: Euro 700.000,00 - Companies Register Office - Modena: 03213240363
Registered with the Administrative Economic Register: MO-368370mailto:info@holostem.com?subject=Web%20contactshapeimage_7_link_0
           
Privacy   |   Cookies    |   Terms of usePrivacy.htmlCookies.htmlTerms_of_use.htmlshapeimage_8_link_0shapeimage_8_link_1shapeimage_8_link_2

Regenerative Medicine from Bench to Bedside


Holostem Terapie Avanzate is the first Italian biotechnological company devoted to the development, manufacture, registration and distribution of Advanced Therapy products based on cultures of epithelial stem cells both for cell therapy and gene therapy.


The main aim of Holostem Terapie Avanzate is to promote epithelial stem cell-based Regenerative Medicine for patients with no alternative therapeutic solutions.


Since 2007, the European Community established that advanced therapy products based on cultured cells are classified as medicinal products, hence they are regulated by the European Medicines Agency (EMA) and need to be produced under the same Good Manufacturing Practices (GMPs) adopted by the pharmaceutical industry for the production of medicines.


Holostem Terapie Avanzate manages a 2.000 sq meters GMP-certified laboratory located in the Centre for Regenerative Medicine (CMR) “Stefano Ferrari” of the University of Modena and Reggio Emilia.